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Measuring regulatory T cell suppression provides important insight into T cell dysfunction in 
autoimmune disease. However, to date, suppression assays are limited by the requirement for 
freshly isolated cells, and significant cell numbers. Here, we present a novel and rapid in vitro 
assay using effector T cell surface expression of both CD25 and CD134 as a surrogate marker of 
regulatory T cell-mediated suppression. This surface marker-based suppression assay works for 
frozen samples and for samples with limited cell numbers. It is also shorter taking two days to 
complete compared to the four days required for proliferation-based assays. Furthermore, this 
assay works with both in vitro expanded and natural Tregs, as well as anti-CD3/anti-CD28 bead-
based and APC stimulation conditions. In conclusion, we have developed and validated a new 
suppression assay for cryopreserved samples with limited cell numbers that may be helpful to 




Suppression Assay; regulatory T cells; CD25; CD134; proliferation 
 
Abbreviations 
eTreg – expanded regulatory CD4+ T cell 
nTreg – ex vivo ‘natural’ CD4+ regulatory T cell 
Teff – effector CD4+ T cell 
d1 – day 1  
d2 – day 2 
d4 – day 4 
CFSE - Carboxyfluorescein succinimidyl ester 
aCD3/aCD28 – anti-CD3/anti-CD28 Dynabeads 
PBMC – peripheral blood mononuclear cells 
  
1. Introduction 
Quantification of immune cell function is paramount to our understanding of the pathogenesis of 
immunological diseases and to identifying successful therapies. In patients with autoimmune 
disease, the regulation of the immune system is of particular interest and CD4+ regulatory T cells 
(Tregs) have been an important research area. CD4+ CD25+FOXP3+ Tregs suppress CD4 T 
cells via multiple mechanisms, leading to decreased cell proliferation, changes in expression of 
cell surface proteins, and diminished production of cytokines. In the study of human disease, 
measurement of suppression in vitro is vital to research and has been achieved through co-culture 
of Tregs and T effector cells (Teff). Methods include measuring cell proliferation (thymidine 
incorporation or CFSE dye dilution); cytokine production (typically IFNγ and TNFα) 
(McMurchy and Levings, 2012); and activation markers (CD69 and CD154) on the cell surface 
(Canavan et al., 2012). Although in vitro assays may not fully reflect in vivo suppression, co-
culture assays do identify defective Treg function (Bacchetta et al., 2006) and demonstrate 
resistance of effector cells (CD4+CD25-) to suppression by Treg in the setting of several 
autoimmune diseases (Lawson et al., 2008; Schneider et al., 2008; Goodman et al., 2009; 
Schneider and Buckner, 2011; Schneider et al., 2013).  
T cell proliferation is dependent on signals via the TCR and co-stimulatory molecule CD28. 
Among the proteins that are expressed in response to T cell activation is IL2Rα (CD25), which is 
very tightly controlled through transcriptional regulation. CD25 is minimally expressed in resting 
CD4 T cells, but is rapidly upregulated upon stimulation of the TCR (Kim et al., 2006). A 
number of other cell surface molecules are rapidly upregulated following TCR signaling 
including OX40 (CD134), ICAM-1 (CD54), CD69, and CD40L (CD154), which have a variety 
of functions such as aiding proliferation, survival, cytokine production, and cell adhesion 
(Tohma et al., 1992; Mardiney et al., 1996; Chatzigeorgiou et al., 2009; Croft et al., 2009).  
Overall, the assessment of Treg mediated suppression of effector T cells has been limited 
due to the number of cells required, the need for long culture times (4-6 days), and the 
complexity of experimental set up of Treg assays. CSFE based co-culture assays have become 
the gold standard of in vitro assays, but consume larger numbers of cells, due to cell loss during 
the CSFE staining process (approx. 50% cells lost), and require 4 days of culture. Measurement 
of proliferation by uptake of tritiated thymidine can be achieved with a limited number of cells, 
but does not allow concurrent assessment of number of cell divisions and the characteristics of 
dividing cells available with flow cytometry techniques. Early activation markers CD69 and 
CD154 have been used to assess suppression (Canavan et al., 2012), (Ruitenberg et al., 2011), an 
approach that decreases the time of co-culture to as few as 7 hours and has been used 
successfully to assess the function of Tregs, which have been enriched or expanded in vitro or 
the target of IL-2 immunotherapy (Berglund et al., 2013; Hannon et al., 2014; Ito et al., 2014; 
Landwehr-Kenzel et al., 2014). However, this assay has barriers due to the need to perform the 
assay within a single extended workday and high reagent costs. In other studies, CD25 and 
CD134 have been used to identify antigen specific responses and their regulation in the context 
of viral infection (Endl et al., 2006; Zaunders et al., 2009; Shaw et al., 2011; Keoshkerian et al., 
2012).  
Our goal was to develop a method to measure events close to the start of cell division, but 
prior to extensive proliferation. To achieve this, we examined the cell surface molecules known 
to be upregulated in activated/proliferating cells at 48 hours (the time in which initial T cell 
division occurs after activation) in order to identify an alternative marker that could be used to 
measure suppression. This study showed that the combined expression of CD25 and CD134 on 
effector cells is a good surrogate for, or additional measure to proliferation that is suppressed by 
Tregs to a similar degree.  
 
2. Materials and methods 
2.1. Subjects 
This study was approved by the Benaroya Research Institute’s Institutional Review Board, and 
all subjects signed written informed consent prior to inclusion in the study. Frozen PBMCs and 
fresh peripheral blood samples were obtained from the Benaroya Research Institute Immune 
Mediated Disease Registry and Repository. In total, cryopreserved samples from 50 healthy adult 
volunteers were used for suppression assays. In addition, six volunteers provided fresh blood 
samples for expanded Tregs, CD4+CD25+ nTregs, or large quantities of Teff from a single 
source as assay controls.  
 
2.2. Autoantibodies and reagents  
Flow cytometry data were acquired on a FACS Canto (BD Biosciences). Teff (CD4+CD25-) 
were stained with CFSE (Invitrogen) and Tregs with eFluor670 (EF670) (eBiosciences) as 
previously published (Schneider and Buckner, 2011). In addition, the following were used: FITC 
anti-CD69; PE CD25, CD54, CD134, CD137, CD152, CD154, CD183 or CD278; PE-Cy5 CD4 
or CD25; PE-Cy7 CD25; BV421 CD279 or CD134; APC-Cy7 CD4; and Live/Dead Aqua 
(Invitrogen). Analysis of cell cycle progression was carried out according to manufacturer’s 
instructions using a FITC BrdU kit (BD Biosciences). Cells were cultured in RPMI1640 HEPES 
media containing 10% pooled human serum, additional L-glutamine, penicillin/streptomycin, 
and sodium pyruvate (Sigma).  
 
2.3. Cell sources  
Unless otherwise specified, experiments used an expanded source of regulatory cells (eTregs) 
from a single healthy control, and effector cells (Teff) were isolated from frozen PBMC. The 
eTregs were generated by isolation of CD4+CD25HICD127- using a FACS Aria (BD) and 
expansion over 14 days with IL-2 (Chiron) and anti-CD3/anti-CD28 (aCD3/aCD28)–coated 
Dynabeads (Invitrogen) (Putnam et al., 2009). The percentage of FOXP3+ cells was verified to 
be greater than 90%. Effector cells (CD4+CD25-) were isolated using MACs kits through 
negative selection for CD4 and positive selection for CD25 (Miltenyi Biotec) (Schneider and 
Buckner, 2011). In experiments using ex vivo Tregs (nTregs), the highest 2% of CD25 stained 
CD4+ cells were isolated from PBMC using a FACs Aria. In these experiments, freshly sorted 
Teffs were the lowest 50% of CD25 stained CD4+ cells. The marker CD127 was not included in 
this isolation strategy, for simplicity, based on previous data showing high (90%) FOXP3 
expression in the cells with the highest 3-5% of CD25 expression (Mikacenic et al., 2014).   
 
2.4. Suppression Assays 
Analysis was carried out at 7 hours,  1 day (20-24 hours, d1), 2 days (44-48 hours, d2), and/or  4 
days (90-96 hours, d4) as indicated. For all time points Teffs (number of cells varied between 
assays) were co-cultured with several ratios of Tregs cells in 96-well plates with anti-CD3/anti-
CD28 Dynabeads (Invitrogen). Tregs and Teff were cultured at ratios between 0:1, 1:2 to 1: 64 in 
doubling dilutions. Where insufficient cells were available ratios of 1:8>1:4>1:2>1:16 were 
prioritized. For analysis, Teff cultured in media alone were used to set gates for the various 
activation markers used or proliferation. EF670 was used to identify Treg; Teff cells were in the 
EF670- gate. Representative gating for 7 hours, 2 days, and 4 days is shown in Figs. S1-S3.  
Flow cytometry was standardized between experiments using eight peak beads (Spherotech). 
For the 7-hour assay, five wells of 50,000 Teff were prepared per condition. These were 
stimulated with Dynabeads (Invitrogen) at a bead:Teff ratio of 1:5 (high) or 1:28 (low). Anti-
CD154 PE was added at start of assay all other markers were cell surface stained at the end of 
assay.  Total cell requirement for this method was approximately 1.8 million Teff and 250,000 
eTregs per person.  
For the 1 day, 2 day, and 4 day experiments 100,000 Teff were plated three times for each 
condition, and Dynabeads were added at a ratio of 1:28 (beads:Teff). Adaptations of this method 
included the use of a 1:35 (beads:Teff) ratio for nTreg experiments, and a 1:4 ratio 
(Teff:irradiated CD4- APC) with additional aCD3 (UCHT1, 5µg/mL) and aCD28 (CD28.2, 
1µg/mL) for APC experiments. When added, Pam3CSK4 (1μg/ml; Invivogen) was included at 
the start of co-culture. Analysis of proliferation by CFSE and activation by cell surface marker 
were carried out on the same cells. For these experiments approximately 2.5 million 
CD4+CD25- and 300,000 Tregs were used for each day of analysis. An adaptation of this 
method used 5,000 Teff plated in triplicate, this required 90,000 Teff and 15,000 nTregs per 
‘miniature’ assay; In these experiments flow cytometry based sorting of 60 million frozen PBMC 
yielded between 20-70,000 nTregs after staining with EF670.  




 ×  100  
where a is the percentage proliferation or marker+ (e.g. CD25+CD134+) in the absence of Tregs 
and b is the percentage proliferation or marker+ in the presence of Tregs.  
 
2.5. Statistical analysis 
Spearman’s rank correlation was used to analyze the relationship between different measures of 
activation/proliferation and suppression. Bland-Altman analysis was used to interrogate bias 
between different measures for activation/proliferation and suppression. Wilcoxon matched pairs 
test was used to compare suppression in the presence/absence of Pam3CSK4. Kruskal-Wallis test 
was used to compare suppression based on source of Teff and Treg in ‘miniature’ assays. FlowJo 
software (Tree Star) was used for all analysis of flow cytometry and Prism (GraphPad Software) 
was used for all statistical analysis.  
  
3. Results 
3.1. CD25 cell surface expression correlates with CFSE-based proliferation at day 4 
CD25 is upregulated in response to T cell stimulation and by IL-2 within 48 hours of initial 
activation, and persists for at least 4 days (Wang et al., 2008). To determine whether CD25 
expression on Teff correlated with their number of cell divisions based on CFSE dilution, co-
culture experiments were performed with Teffs (CD4+CD25-) from 14 healthy volunteers. Teffs 
were labelled with CFSE, and then placed in culture with in vitro expanded Tregs (eTregs) 
(Putnam et al., 2009) and anti-CD3/anti-CD28 coated Dynabeads. These experiments showed 
that the percentage of proliferating cells determined by dye dilution compared to the percentage 
of CFSE labeled cells that were CD25+ on day 4 of co-culture were highly correlated (r=0.995, 
Fig. 1a). The suppression of both of these measures by eTregs was also highly correlated 
(r=0.996, Fig. 1b). Bland-Altman analysis of suppression demonstrated a low overall bias of 
1.6% (equivalent to 1.6% difference in suppression between the two methods), but this was not 
uniform (Fig. 1c). The 95% limits of agreement were -3.6 to 6.9%. The level of expression of 
CD25 (measured by mean fluorescent intensity) on the surface of the cells also correlated with 
proliferation but was less well correlated than percentage of CD25+ cells (Fig. S4). These data 
demonstrate a strong agreement between CD25 expression and proliferation particularly when 
percentage suppression is in the mid-range (40-60% suppression), which our group has found to 
be most sensitive to differences between individuals (Schneider and Buckner, 2011). 
 
3.2. The suppression of surface CD25 at day 2 predicts suppression of proliferation at day 4.  
To shorten the duration of this assay, cell surface markers were assessed at days 1 and 2, and 
compared to day 4 proliferation. A single cell division is typically demonstrable by CFSE 
dilution on day 2 of co-culture. At this time-point only 6-21% of Teff cultured alone have 
divided (Fig. 1d) while 16-40% of Teff expressed CD25 (Fig. 1e). In co-culture assays, cell 
division at day 2 correlated with proliferation on day 4 (r=0.945, Fig. 1f) and suppression of 
CD25 expression on day 2 correlated with suppression of proliferation on day 4 (r=0.960, Fig. 
1g). The overall bias for both proliferation and CD25 as measures was low (0.8% and -1.0% 
respectively). However, limits of agreement were higher than 20% for both these comparisons 
(Fig. 1h) and were particularly variable when suppression was low. Thus, neither cell division as 
measured by CFSE or expression of CD25 alone were adequate markers for suppression on day 
2.   
In experiments concurrent with the above assays, the 7-hour suppression assay developed by 
Canavan et al were performed(Canavan et al., 2012) . We performed the assay using two 
different levels of anti-CD3/anti-CD28 beads: a “high” 1:5 ratio of Teff:beads, as per the 
published method, and a “low” 1:28 ratio of Teff:beads as per our standard 4 day assay. 
Suppression of CD69+CD154+ at 7 hours was correlated with suppression of proliferation on 
day 4 of culture when either high (r=0.721, p<0.001) or low (p=0.926, p<0.001) concentrations 
of beads were used. However, despite the high correlation, the level of suppression observed 
utilizing this method, with either high or low beads,  was lower than suppression measured on 
day 4 (bias was 53% and 24%, respectively, Fig. S5).  Thus, we went on to perform further 
experiments with a focus on development of a 2-day assay.  
 
3.3. Additional surface markers improve assessment of suppression at earlier time points 
 
Complementary cell surface markers were investigate in an attempt to remove the non-uniform 
bias described above (Fig. 1c,h,i). In preliminary experiments (data not shown), the expression 
and suppression of CD54, CD134, CD137, CD152, CD183, CD278, and CD279 on days 1, 2, 
and 4 were compared to CD25 and proliferation. From these data, CD54 and CD134 were 
chosen for further investigation. In experiments with Teff from 10 additional healthy subjects, 
suppression was calculated based on the percentage of cells on days 1, 2 or 4 that were CD25+, 
CD25+CD54+, CD25+CD134+, or CD25+CD54+CD134+. On day 4, correlation between CD25 
alone and proliferation remained the highest (Fig. 2i-l).  However, on day 1 and day 2, 
combinations of CD25+CD134+CD54+/- had higher correlation values than CD25 alone 
(r=0.772 vs. r>0.9 Fig. 2a-d, and r=0.925 vs r>0.94 Fig. 2e-h, respectively). Thus, a combination 
of cell surface markers CD25, CD134 and CD54 could be used to assess suppression at day 2. 
Although the addition of CD54 on day 1 or day 2 improved correlation coefficients, in future 
experiments, analysis was restricted to CD25+CD134+ on day 1 and day 2, and analysis of 
CD25 alone on day 4, in order to simplify the flow cytometry fluorophore scheme.  
 
3.4 Surface marker-based suppression assay correlates with proliferation-based suppression 
assay when using nTregs or APC activation.  
To investigate the applicability of this method to alternative in vitro systems, the expression of 
CD25 or the combination of CD25+ CD134 was compared to measurement of proliferation in 
co-culture with different sources of regulation (nTregs) and stimulation (APC + soluble anti-CD3 
+ soluble anti-CD28).  
We found that despite a lower maximum suppression with nTregs (suppression of 76%, 
67%, 60% at a dilution of 1:2, for 3 subjects) compared to eTregs (suppression of 97%, 95%, 
92%, for the same subjects), the correlation between suppression of proliferation and suppression 
of CD25 on day 4 was strong for both either nTregs and eTregs (r=0.974 and r=0.959, Fig. 3a). 
Suppression by nTregs of CD25+CD134+ on day 2, and proliferation on day 4 were significantly 
correlated (r=0.647, p=0.002) but to a lesser degree than these measures by eTregs (r=0.939). 
This may reflect differences in the function of these two types of Tregs with respect to early 
activation. Alternatively, this result may be due to the increased variance of the assay when low 
level of suppression are present, as was the case in this specific assay containing nTreg.  
An alternative form of activation was also studied by using a co-culture assay in which 
soluble anti-CD3 and autologous antigen presenting cells (APC) were used for stimulation. 
Suppression of cell surface markers was lower than suppression of proliferation using APC 
compared to bead based activation. However, suppression of proliferation was correlated with 
suppression of cell surface markers on both days 2 and 4 for APC (r=0.8765 and r=0.9382, 
respectively) and bead based conditions (r=0.963 and r=0.983, respectively; Fig. 3c,d). This 
indicates that our assay could be used to assess Treg mediated suppression with a variety of 
Tregs and activation conditions. 
 
3.5. CD25 cell surface expression correlates with BrdU-based proliferation. 
An alternative measure of proliferation is the incorporation of BrdU into DNA during S-phase of 
the mitosis.  We performed co-culture assays with BrdU and found low incorporation of BrdU 
into cells during 0-24 hours, but between 24 hours and 48 hours cells as cells entered S-phase; 
BrdU staining correlated well with CD25+CD134+ expression (r=0.9823, p<0.001) and with the 
number of cells proliferating in concurrent CFSE based assays (r=0.978, p<0.001, Fig. S6).  
These findings indicate that staining for cell surface CD25 and CD134 mirrors proliferation 
using two distinct measures. 
 
3.6. Suppression of surface markers mirrors the reduction in suppression of proliferation caused 
by addition of the TLR 1/2 agonist Pam3CSK4.  
To address the ability of this assay to detect differences in the response of effector T cells to Treg 
mediated suppression in vitro, we performed suppression assays in the presence or absence of the 
TLR1/2 agonist Pam3CSK4. The toll-like receptor 1/2 agonist Pam3CSK4 reduces suppression 
measured by proliferation (CFSE) in a 4-day suppression assay (Mikacenic et al., 2014). We 
tested the suppression of proliferation and CD25/CD134 after 2-4 days of co-culture of Tregs 
and Teff from 13 healthy individuals with and without addition of Pam3CSK4. The relationship 
between suppression of proliferation and suppression of CD25 on day 4 or CD25+CD134+ on 
day 2 was not different with Pam3CSK4 compared to without Pam3CSK4. As expected, addition 
of Pam3CSK4 reduced suppression of proliferation on day 4 of the assay (p=0.024, 1:4 ratio), 
this was mirrored by a reduction in suppression of CD25+ on day 4 (p=0.007), and 
CD25+CD134+ on day 2 (p=0.0105, Fig. 4a-c). These results indicate an ability to demonstrate 
TLR mediated impaired suppression with the 2-day assay. 
 
3.7 Surface marker-based suppression assay is effective for frozen PBMC and low volume blood 
samples.  
A goal of developing this assay was to not only shorten and simplify the Treg assay, but also to 
miniaturize the assay for use with frozen PBMC or very low volume blood samples. 
Additionally, our goal was to be able to use this assay to demonstrate differences in both the 
function of Treg and the ability of Teff to be suppressed between individual subjects. To test this 
frozen cells from four donors (referred to as A-D; Fig. 5a) were thawed and sorted using a FACS 
Aria. Teffs (CD4+ T cells in the lowest 50% of CD25 expression) and nTregs (highest 2% of 
CD25 expression CD4+ T cells) were co-cultured. Assays were performed with 5000 Teffs per 
well (plated in triplicate and combined for analysis) and Teff:Treg ratios of 1:2 to 1:16, Tregs 
were stained with EF670. Combinations of Tregs and Teffs from different samples tested 
reproducibility and demonstrated differences between subjects.  Of 16 possible combinations of 
nTregs and effectors, there were sufficient cells for 10 different pairs (Fig. 5a). On day 2 the 
number of effectors expressing CD25 in response to bead stimulation, without suppression by 
Tregs, were for donor A 23%, donor B 17%, donor C 14%, and donor D 17% (horizontal line in 
Fig. 5b).  In this set of assays, there were differences in activation measured at a 1:4 Treg:Teff 
ratio between donors (p=0.013, Fig. 5b). There were also significant differences in suppression 
dependent on the donor of the Teff (p=0.029, Fig. 5c) but not driven by the source of Treg 
(p=0.987, data not plotted) nor by the level of activation of the Teff. These data demonstrate the 
consistency of this miniaturized assay and its ability to detect differences in the responsiveness 




In this study, we demonstrate the use of cell surface activation markers to determine suppression 
in in vitro co-culture suppression assays.  Notably we demonstrate a very strong correlation 
between CD25 expression of CD4 effectors at day 4 and CFSE based cell division. Application 
of an assay that utilizes percentage CD25 as a measure at day 4, would limit manipulation, and 
the resulting loss of viable CD4 effector T cells prior to the co-culture assay.  Further, we have 
shown that there is a good correlation between the percentage CD25+ CD134+ T cells at day 2 
with CFSE-based proliferation on day 4. Application of this assay has the benefit of a shortened 
assay and manageable time constraints on the performance of the assay. This assay yields similar 
results under different stimulation conditions and multiple regulatory T cell types, and captures 
the influence of known factors that impair suppression. Finally, an adaption of this method to a 
miniaturized assay, using 5,000 Teffs per well, showed good intra assay reproducibility and 
demonstrated differences between subjects in suppression. Application of this assay could 
dramatically reduce cell requirements in addition to the other benefits of the 2-day assay.    
The strengths of this study are the examination of a progression of assay adaptations in a 
variety of subjects and testing in different experimental settings. Although agreement between 
‘gold standard’ CFSE-based assays and the alternative assays examined was effected by non-
uniform bias the middle range of the assay (30-60% suppression) is probably the most 
biologically important and is similar in both the day 4 CD25 and day 2 CD25/CD134 assays. In 
this range both of these assays should be able to detect differences of 20% in suppression, which 
is of a similar magnitude to the differences between patients with remitting-relapsing multiple 
sclerosis or diabetes and healthy controls previously published by our group (Schneider et al., 
2008; Schneider et al., 2013). Our group has also shown that a TLR 1/2 agonist, Pam3CSK4, 
reduces suppression when added to co-culture assays(Mikacenic et al., 2014). In this study, we 
were able to replicate this observation using the day 2 CD25/CD134 assay.  
The role of CD25 and CD134 in the immune system could mean that in some circumstances 
they may provide additional information to analysis of proliferation but their expression could 
also be altered by some immune defects. In the current study, CD25 staining was consistent 
between individuals suggesting common polymorphisms in the IL-2RA gene did not significantly 
alter binding of the CD25 antibody or the upregulation of CD25, as it correlates with 
proliferation in response to activation.  In addition, in vitro CD134 antagonizes Treg mediated 
suppression (Croft et al., 2009), therefore if OX40 signaling is of interest these assays would not 
be appropriate.  
Despite these caveats, the measurement of CD25 and CD134 surface expression at 2-5 days of 
culture has been successfully employed by others to detect antigen specific cells from fresh and 
frozen samples (Endl et al., 2006; Zaunders et al., 2009; Keoshkerian et al., 2012). Following 
this example Shaw and colleagues investigated both suppression of proliferation and suppression 
of CD25+CD134+ cells by peripheral and mucosal (rectal) responders and Tregs from 
seronegative individuals and individuals with HIV able to maintain their viral RNA load (Shaw 
et al., 2011). They showed no difference in suppression of proliferation, at 60-84 hours of 
culture, between these three groups of individuals; however, suppression calculated from 
CD25+CD134+ was different between these three groups. The reasons for this discrepancy are 
unknown but support our observation (Fig. 3c) that suppression of CD25+CD134+ and 
suppression of proliferation may be disparate under APC based stimulation, used by Shaw et al., 
compared to bead-based stimulation. This also highlights the importance of the level of 
stimulation used in these assays on the outcome. It is vital that the source of stimulation is 
optimized and suggest that the  CD25+CD134+ subset of effector T cells alone at 48 hours be 
above 10% in order to attain measurable and reliable levels of suppression.  
In this study, measurement of CD154 and CD69 at 7 hours was also assessed. Our data 
showed good correlation of this method with suppression of proliferation at 4 days supporting 
the initial description of the assay by Canavan et al. (Canavan et al., 2012). Despite the good 
correlation, the 7-hour assay underestimated suppression of proliferation at 4 days by at least 
25% and therefore a 2-day assay was pursued. We chose to quantify CD69+CD154+ cells 
because in preliminary experiments a combination of markers gave the highest suppression. 
Whereas, Canavan et al. analyzed CD69+ and CD154+ cells separately, finding that CD154+ 
had better agreement with suppression of proliferation than CD69+. Upon reanalysis, re-gating to 
measure CD69+, CD154+, and proliferation precursors instead of all proliferating cells (Wells et 
al., 1997), our data still showed that activation at 7 hours underestimates proliferation at 4 days.  
Here, we have outline three suppression assay methods, all applicable to cryopreserved cells. 
Although all these assays can measure defects in suppression, they will be most useful in 
different contexts. Analysis of CD25+ on day 4 of culture, as opposed to proliferation, requires 
less manipulation of cells, less cell death through CFSE staining, and would simplify 
experimental procedures. In particular, in studies analyzing large numbers of participants 
removing the need to CFSE stain should save a substantial amount of time and assay variation. 
However, Tregs or Teff must be labeled in some way to allow separation of these cells during 
flow cytometry analysis; in the assays described here, Tregs were stained with EF670. Therefore, 
this assay would be most useful to measure suppression of multiple Teff by a single source of 
Treg in research with a large numbers of participants, where there are no stringent constraints on 
time or cell number. Alternatively, where a shorter assay is required or early events in cell 
activation are of interest, expression of CD25 and CD134 on day 2 of co-culture would be a good 
method. In studies where cell number is a constraint, our data suggest that a miniature (5,000 
Teff per well) suppression assay measuring CD25+CD134+ at day 2 could be employed. 
Although, the choice of staining Teff or Treg should be dependent on which cell type is most 
limiting. Even if CFSE-based analysis of proliferation is employed measurement of CD25 and 
CD134 is recommended because it is likely to give additional biological information in some 
experimental, tissue, or disease settings.  
In conclusion, we report a number of adaptations of suppression assays that should suit a 
range of different research questions. The ability to measure suppression more simply should 
allow researchers to make full use of arduously collected biobank samples. This in turn should 
provide a more comprehensive understanding of the immunology of a variety of diseases.   
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FIGURE LEGENDS  
Figure 1. Suppression of CD25 Teff surface expression correlates with suppression of Teff 
proliferation. (a) Correlation of CD25 surface expression on Teff and CFSE-based Teff 
proliferation at day 4. (b) Correlation of percentage suppression of CD25+ Teff and percentage 
suppression of CFSE-based Teff proliferation at day 4. (c) Bland-Altman plot of percentage 
suppression of CD25 surface expression on Teff and percentage suppression of CFSE-based Teff 
proliferation at day 4. (d) For one representative individual, the dilution of CFSE through cell 
division and expression of CD25 on Teff are shown for day 2. (e) CD25 surface expression and 
CFSE-based proliferation on day 2 from Teff cultured with anti-CD3/anti-CD28 beads alone. (f) 
Correlation of percentage suppression of CFSE-based Teff proliferation at days 2 and 4. (g) 
Correlation of percentage suppression of CD25+ Teff at day 2 and percentage suppression of 
CFSE-based Teff proliferation at day 4. (h) Bland-Altman plot of percentage suppression of 
CD25+ Teff at day 2 and percentage suppression of CFSE-based Teff proliferation at day 4.  For 
day 4 (a-c), 96 data points representing different Treg:Teff ratios for 14 healthy controls are 
shown (7 experiments with no replicated samples). From the same experiments on day 2 (e-h), 
70 data points from 11 of 14 healthy controls due to low cell numbers from three participants. 
Spearman’s rank correlation coefficient: a (r=0.995, P<0.0001), b (r=0.996, P<0.0001), f 
(r=0.945, P<0.0001), and g (r=0.960, P<0.0001); dashed line shows y=x, solid circles show 
Teff+Treg, and open circles in a show Teff alone. Bland-Altman analysis was used to compare 
methods in c (bias=1.6%) and h (bias= 0.9%). The solid line shows average bias, dotted lines 
95% CI for agreement. No statistical comparison was made for (e), median and interquartile 
range are shown.  
 Figure 2. Suppression of both CD54 and CD134 Teff surface expression also correlate with 
suppression of Teff proliferation. Correlation of percentage suppression of CD25+ Teff (a, day 
1; e, day 2; i, day 4) and percentage suppression of CFSE-based Teff proliferation at day 4. 
Correlation of percentage suppression of CD25+CD54+ Teff (b, day 1; f, day 2; j, day 4) and 
percentage suppression of CFSE-based Teff proliferation at day 4. Correlation of percentage 
suppression of CD25+CD134+ Teff (c, day 1; g, day 2; k, day 4) and percentage suppression of 
CFSE-based Teff proliferation at day 4. The median frequency of CD25+CD134+ on day 2 in 
Teff cultured without Treg suppression was 25% (range 10-41%). Correlation of percentage 
suppression of CD25+CD54+CD134+ Teff (d, day 1; h, day 2; l, day 4) and percentage 
suppression of CFSE-based Teff proliferation at day 4. Spearman’s rank correlation coefficients: 
a (r=0.772; P<0.0001), b (r=0.866; P<0.0001), c (r=0.900; P<0.0001), d (r=0.953; P<0.0001), e 
(r=0.925; P<0.0001), f (r=0.915; P<0.0001), g (r=0.943; P<0.0001), h (r=0.955; P<0.0001), i 
(r=0.962; P<0.0001), j (r=0.961; P<0.0001), k (r=0.952; P<0.0001), and l (r=0.950; P<0.0001). 
Depending on the number of cells available ratios of 1:2-1:16 Treg:Teff were included for each 
sample and compared to Teff with anti-CD3/anti-CD28  beads for between  5 to 14 healthy 
controls from 3 experiments with no replicates. Not all combinations of markers were stained in 
all assays.  
 
Figure 3. Surface marker-based suppression assay correlates with proliferation-based 
suppression assay when using nTregs or APC activation. (a) Correlation of percentage 
suppression of CD25+ Teff at day 4 and percentage suppression of CFSE-based Teff proliferation 
at day 4; solid circles = nTregs, and open circles = eTregs. (b) Correlation of percentage 
suppression of CD25+CD134+ Teff at day 2 and percentage suppression of CFSE-based Teff 
proliferation at day 4; solid circles = nTregs, and open circles = eTregs. The median frequency of 
CD25+CD134+ on day 2 in Teff cultured without Treg suppression was 20% (range 7-22%). 
 (c) Correlation of percentage suppression of CD25+ Teff at day 2 and percentage suppression of 
CFSE-based Teff proliferation at day 4; solid circles = APC activation, and open circles = Bead 
activation. (d) Correlation of percentage suppression of CD25+CD134+ Teff at day 2 and 
percentage suppression of CFSE-based Teff proliferation at day 4; solid circles = APC activation, 
and open circles = Bead activation. Spearman’s rank correlation coefficients: a (nTregs: r= 
0.974, p<0.0001 eTregs: r=0.959, p<0.0001), b (nTregs: r= 0.646, p=0.0016 eTregs: r=0.939, 
p<0.0001), c (APC: r= 0.938, p<0.0001 Beads: r=0.983, p<0.0001), d (APC: r= 0.877, p<0.0001 
Beads: r=0.963, p<0.001). nTregs were sorted from two subjects, eTregs were expanded from 
three subjects, and grouped for analysis, and Teff were from six subjects. 
 
Figure 4. Comparison of surface marker-based suppression assay and CFSE-based 
suppression assay in the presence of Pam3CSK4. (a) Percentage suppression of 
CD25+CD134+ Teff at day 2 in the absence and presence of Pam3CSK4. The median frequency 
of CD25+CD134+ on day 2 in Teff cultured without Pam3CSK4 was 57% (range 30-82%). 
 (b) Percentage suppression of CD25+ Teff at day 4 in the absence and presence of Pam3CSK4. 
(c) Percentage suppression of CFSE-based proliferation at day 4 in the absence and presence of 
Pam3CSK4. Wilcoxon test of paired data: (a) *P=0.011, (b) ***P=0.001, and (c) **P=0.002. 
Data from 13 healthy controls are shown with cells at Tregs:Teff ratios of 1:4. 
 
Figure 5: Measurement of suppression of CD25+CD134+ expression on day 2 using 5,000 
Teff per well. (a) Outline of the source of Tregs and Teff from four donors (A, B, C and D). 
Cells were combined in four autologous and six allogenic pairings depending on number of cells 
recovered from sorting.  (b) Percentage CD25+CD134+ Teff at a 1:4 ratio of Tregs:Teff. 
Horizontal line indicates the maximum proliferation for Teff incubated with anti-CD3/anti-CD28 
beads without Tregs (not included in Kruskal-Wallis Test). (c) Percentage CD25+CD134+ 
suppression calculated from the data in Figure B.  The median frequency of CD25+CD134+ on 
day 2 in Teff cultured without Treg suppression was 17% (range 14-23%). For b and c, the x-axis 
indicates the source of the Teff for the assay. The shape of the symbol indicates the source of 
Treg: subject A = square, subject B = triangle, subject C = circle, subject D = diamond. Filled 
symbols indicate cells from the same subject.  Kruskal-Wallis Test: (b) P=0.013, and (c) 
P=0.029.    
 
 
 
